Biomedical researchers lax about validating antibodies for experiments

Nearly one-third of junior scientists spend no time validating antibodies, even though accurate results depend on these reagents working as expected, according to the results of a survey reported today in BioTechniques. "This is quite alarming," says Matthias Uhlén, a protein researcher at the Royal Institute of Technology in Stockholm who heads an international working group on antibody validation, but who was not directly involved in the survey.